Title: Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree
of malignant esophageal stenosis
Version: 1 Date: 17 Jul 2023
Reviewer's report:
Comments to the author
I am grateful for the opportunity to review this interesting manuscript entitled: "Impact of
preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant
esophageal stenosis". This report is interesting because it focused on the improvement of
MES according to neoadjuvant chemotherapy regimen. However, your manuscript has major
problems as following.
Comments
1. There are a lot of previous reports which suggested better local control of DCF for esophageal
cancer compared to other regimens, therefore this manuscript does not give us novel information.
You should show clinical benefit, such as the improvement of nutritional status and food intake
after neoadjuvant therapy.
2. You use stenosis index (SI) as an indicator of stenosis, but I suspect if SI is reproducible
indicator or not. I cannot understand the definition of length of stenosis, because the start and end
points were not clear. I concern that this length will vary according to persons of measurement.
Minor comments
1. Page 6, Line 6-10
Were all of your cohort received R0 resection or not? You should mention about it.
2. Page 16, Line 4-16
This paragraph mentioned about PTX for esophageal cancer, but it was not used for your cohort.
You had better delete this paragraph.
3. Figure 2
OS was worse in DCF group than in FP group because of the difference of oncological
background between two groups. I think that survival information is not necessary in this
manuscript because it will not help your conclusion in your report.
Title: Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree
of malignant esophageal stenosis
Version: 1 Date: 17 Jul 2023
Reviewer's report:
Comments to the author
I am grateful for the opportunity to review this interesting manuscript entitled: "Impact of
preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant
esophageal stenosis". This report is interesting because it focused on the improvement of
MES according to neoadjuvant chemotherapy regimen. However, your manuscript has major
problems as following.
Comments
1. There are a lot of previous reports which suggested better local control of DCF for esophageal
cancer compared to other regimens, therefore this manuscript does not give us novel information.
You should show clinical benefit, such as the improvement of nutritional status and food intake
after neoadjuvant therapy.
2. You use stenosis index (SI) as an indicator of stenosis, but I suspect if SI is reproducible
indicator or not. I cannot understand the definition of length of stenosis, because the start and end
points were not clear. I concern that this length will vary according to persons of measurement.
Minor comments
1. Page 6, Line 6-10
Were all of your cohort received R0 resection or not? You should mention about it.
2. Page 16, Line 4-16
This paragraph mentioned about PTX for esophageal cancer, but it was not used for your cohort.
You had better delete this paragraph.
3. Figure 2
OS was worse in DCF group than in FP group because of the difference of oncological
background between two groups. I think that survival information is not necessary in this
manuscript because it will not help your conclusion in your report.
Please review this paper.
user
Title: Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree
of malignant esophageal stenosis
Version: 1 Date: 17 Jul 2023
Reviewer's report:
Comments to the author
I am grateful for the opportunity to review this interesting manuscript entitled: "Impact of
preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant
esophageal stenosis". This report is interesting because it focused on the improvement of
MES according to neoadjuvant chemotherapy regimen. However, your manuscript has major
problems as following.
Comments
1. There are a lot of previous reports which suggested better local control of DCF for esophageal
cancer compared to other regimens, therefore this manuscript does not give us novel information.
You should show clinical benefit, such as the improvement of nutritional status and food intake
after neoadjuvant therapy.
2. You use stenosis index (SI) as an indicator of stenosis, but I suspect if SI is reproducible
indicator or not. I cannot understand the definition of length of stenosis, because the start and end
points were not clear. I concern that this length will vary according to persons of measurement.
Minor comments
1. Page 6, Line 6-10
Were all of your cohort received R0 resection or not? You should mention about it.
2. Page 16, Line 4-16
This paragraph mentioned about PTX for esophageal cancer, but it was not used for your cohort.
You had better delete this paragraph.
3. Figure 2
OS was worse in DCF group than in FP group because of the difference of oncological
background between two groups. I think that survival information is not necessary in this
manuscript because it will not help your conclusion in your report.
assistant